Target intelligence / Profile preview

Replication factor C subunit 3 (RFC3)

Target
RFC3
Molecular classification
Other (subunit of DNA clamp loader complex), DNA replication factor, Protein complex subunit (Replication factor C complex)
01

Overview

Replication factor C subunit 3 (RFC3) is a 38 kDa protein encoded by the RFC3 gene in humans and is one of five distinct subunits (140, 40, 38, 37, and 36 kDa) of the replication factor C (RFC) complex. The RFC complex acts as a DNA clamp loader, essential for elongation of primed DNA templates by DNA polymerases delta and epsilon. Specifically, RFC3 facilitates interaction between the largest 140 kDa subunit (RFC1) and a core RFC subcomplex comprising the 36, 37, and 40 kDa subunits, and is necessary for ATP-dependent loading of proliferating cell nuclear antigen (PCNA) onto DNA—an essential step in DNA replication and repair. Mutations or altered expression of RFC3 are implicated in cancer biology and rare developmental disorders. Supporting details: - RFC3 has documented protein–protein interactions, notably with PCNA, BRD4, CHTF18, and other RFC subunits. - Its gene is referenced in multiple databases: HGNC: 9971, NCBI Gene: 5983, UniProtKB: P40938. - No direct drugs appear in clinical use that target RFC3 specifically, though it and related pathways are being explored as therapeutic and prognostic biomarkers in oncology.

Other names
RFC38A1 38 kDa subunitRF-C 38 kDa subunitActivator 1 38 kDa subunitActivator 1 subunit 3Replication factor C 38 kDa subunit38 kD subunitMGC5276
02

Mechanism of action

Drugs targeting RFC3 would be expected to interfere with DNA replication/repair by inhibiting ATP-dependent loading of PCNA onto DNA (no approved drugs directly target RFC3 as of the latest data)

03

Biological functions

DNA replicationDNA repairCell cycle progressionProtein-protein interaction (as part of RFC complex)
04

Disease associations

Cancer (notably in head and neck squamous cell carcinoma)Microcephaly, growth deficiency, seizures, and brain malformations (genetic syndromes)
05

Safety considerations

Generic to DNA replication inhibitors: cytotoxicitymyelosuppressionpotential for genotoxicityeffects on rapidly dividing normal cells (speculative; no RFC3-specific clinical inhibitors as of the latest data)
06

Biomarkers

RFC3 has been investigated as a prognostic biomarker and potential therapeutic target in certain cancers, including head and neck squamous cell carcinoma

Beyond the preview

Go deeper on Replication factor C subunit 3 (RFC3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Replication factor C subunit 3 (RFC3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call